SCHEMBL6451504

SCHEMBL6451504

CC(C)(C)c1ccc(O)c(-c2nc(-c3nccc4ccccc34)n[nH]2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
PLK4 O00444 1/20 0.37
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
CHUK O15111 1/20 0.37
PDPK1 O15530 1/20 0.37
JAK2 O60674 1/20 0.37
ROCK2 O75116 1/20 0.37
MAP4K4 O95819 1/20 0.37
PAK4 O96013 1/20 0.37
CHEK2 O96017 1/20 0.37
ABL1 P00519 1/20 0.37
NTRK1 P04629 1/20 0.37
PRKCG P05129 1/20 0.37
INSR P06213 1/20 0.37
LCK P06239 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6457130 0.85 GRK6 (0.43) ADORA2AKMT2AMEN1POLBGAA
SCHEMBL6449802 0.85 GUSB (0.43) ADORA2AKMT2AGAAITKNPC1
SCHEMBL6450301 0.83 GRK6 (0.43) ADORA2AKMT2AMEN1NPC1RAB9A
SCHEMBL6450144 0.83 IDO1 (0.44) ADORA2AKMT2AMEN1DCUN1D1ALDH1A1
SCHEMBL6451195 0.83 ADORA2A (0.41) ADORA2AKMT2ACHEK1CHEK2ITK
SCHEMBL6450636 0.83 GUSB (0.48) ADORA2AKMT2AMEN1GAANPC1
SCHEMBL6459671 0.82 ADORA2A (0.57) ADORA2AKMT2AMEN1POLBGAA
SCHEMBL6451270 0.82 KMT2A (0.40) ADORA2AKMT2AMEN1GAANPC1
SCHEMBL6450009 0.81 KMT2A (0.40) ADORA2AKMT2AMEN1FGFR1KDR
SCHEMBL6450502 0.81 ADORA2A (0.43) ADORA2AKMT2AMEN1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC ADORA2A 1442/4885KMT2A 3600/4885MEN1 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.